Tomorrow Morphosys will report her past quarter's results. For the current book year the analysts expect a total revenue of 49 million euros. This is rather significant lower than the revenue over 2015 of 106,22 million euros.
The analysts expect for 2016 a net loss of 54 million euros. For this year the analyst's consensus of Morphosys 's result per share is a loss of 1,93 euros. Based on this the price/earnings-ratio equals -20,09.
For this year the analysts expect no dividend payments of Morphosys . On average the biotech company yields a rather limited dividend yield of around 0,36 percent.
The stock Morphosys is being covered by 8 fundamental analysts. The average target price for the stock is at 59,62 euros. This is around 53 percent more than the current stock price of 38,77 euros. The 3 most recent recommendations for German were provided by Goldman Sachs (hold, 50,00 euros), Oddo Seydler Bank (buy, 66,00 euros) and HSBC (hold, 43,00 euros).
Based on the number of outstanding shares Morphosys 's market capitalization is around 1,01 billion euros.The stock closed last Friday at 38,77 euros.
ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.